Skip to main content

Table 2 Treatment-related adverse events: worst grade per patient in all cycles in at least 10% of all patients, n (%)

From: Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

Adverse event

Gradea

Total

1

2

3

4

5

Blood and lymphatic system disorders

 Hypertension

3 (16.7)

1 (5.6)

2 (11.1)

0

0

6 (33.3)

 Vaginal hemorrhage

2 (11.1)

0

0

0

0

2 (11.1)

Endocrine disorders

 Hypothyroidism

7 (38.9)

0

0

0

0

7 (38.9)

Metabolism and nutrition disorders

 Hypertriglyceridemia

5 (27.8)

1 (5.6)

0

0

0

6 (33.3)

 Decreased appetite

0

2 (11.1)

0

0

0

2 (11.1)

Respiratory, thoracic, and mediastinal disorders

 Dysphonia

2 (11.1)

0

0

0

0

2 (11.1)

Gastrointestinal disorders

 Nausea

4 (22.2)

0

0

0

0

4 (22.2)

 Abdominal pain

2 (11.1)

0

0

0

0

2 (11.1)

 Diarrhea

2 (11.1)

1 (5.6)

0

0

0

3 (16.7)

 Mouth ulceration

1 (5.6)

1 (5.6)

0

0

0

2 (11.1)

Renal and urinary disorders

 Proteinuria

8 (44.4)

0

0

0

0

8 (44.4)

 Hematuria

7 (38.9)

0

0

0

0

7 (38.9)

Skin and subcutaneous tissue disorders

 Rash

1 (5.6)

1 (5.6)

0

0

0

2 (11.1)

 Palmar-plantar erythrodysesthesia syndrome

1 (5.6)

1 (5.6)

0

0

0

2 (11.1)

General disorders and administration site conditions

 Fatigue

7 (38.9)

4 (22.2)

0

0

0

11 (61.1)

Lab examinations

 Leucopenia

2 (11.1)

1 (5.6)

0

0

0

3 (16.7)

 ALT increased

2 (11.1)

0

0

0

0

2 (11.1)

 Amylase increased

3 (16.7)

1 (5.6)

0

0

0

4 (22.2)

 Conjugated bilirubin increased

5 (27.8)

0

0

0

0

5 (27.8)

 Neutropenia

2 (11.1)

0

2 (11.1)

0

0

4 (22.2)

 AST increased

3 (16.7)

0

0

0

0

3 (16.7)

 Hyperbilirubinemia

2 (11.1)

0

0

0

0

2 (11.1)

 Unconjugated bilirubin increased

2 (11.1)

0

0

0

0

2 (11.1)

 Blood urea increased

2 (11.1)

0

0

0

0

2 (11.1)

 Thrombocytopenia

2 (11.1)

0

0

0

0

2 (11.1)

  1. Patients with multiple events in the same category are counted only once in that category; patients with events in more than one category are counted once in each of those categories
  2. ALT alanine amino-transferase, AST aspartate amino-transferase
  3. aGraded per National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0